Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can
Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC). The trial is designed to complement the ongoing clinical program and subsequently broaden the development of CAN04. The phase Ib trial is planned to be performed in up to 30 patients in France and Spain. The current estimate is to start therapy in the first patient in the end of Q2 2021.Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP).